Integrative Cancer Therapies
Share

Integrative Cancer Therapies

2014 Impact Factor: 2.361
2014 Ranking: 131/211 in Oncology | 5/24 in Integrative & Complementary Medicine
Source: 2014 Journal Citation Reports ® (Thomson Reuters, 2015)

EDITOR
Keith I. Block, MD University of Illinois at Chicago, Institute for Integrative Cancer Care, USA

eISSN: 1552695X| ISSN: 15347354|Current volume: 14|Current issue: 6 Frequency: Bi-monthly

As of January 2016, Integrative Cancer Therapies will become a Gold open access publication publishing under a Creative Commons license and requiring no subscription to access.

 
ICT is the first journal to spearhead and focus on a new and growing movement in cancer treatment. The journal emphasizes scientific understanding of alternative medicine and traditional medicine therapies, and their responsible integration with conventional health care. Integrative care includes therapeutic interventions in diet, lifestyle, exercise, stress care, and nutritional supplements, as well as experimental vaccines, chrono-chemotherapy, and other advanced treatments. Contributors are leading oncologists, researchers, nurses, and health-care professionals.

The journal presents scientifically rigorous original research, case studies, current literature reviews, educational roundtables, and commentary on key topics such as:

is the first journal to spearhead and focus on a new and growing movement in cancer treatment. The journal emphasizes scientific understanding of alternative medicine and traditional medicine therapies, and their responsible integration with conventional health care. Integrative care includes therapeutic interventions in diet, lifestyle, exercise, stress care, and nutritional supplements, as well as experimental vaccines, chrono-chemotherapy, and other advanced treatments. Contributors are leading oncologists, researchers, nurses, and health-care professionals.The journal presents scientifically rigorous original research, case studies, current literature reviews, educational roundtables, and commentary on key topics such as:
  • Treatment strategies
  • Evaluations of current therapies
  • Models for integrating complementary and conventional treatment in clinical practice
  • Interventions from alternative and traditional medicine
  • Implementing quality-of-life assessment and counseling in the clinical setting
  • Cancer rehabilitation during and following cancer treatments
  • Potential interactions of cancer chemotherapy drugs with frequently used dietary supplements
  • Implementing integrative cancer care strategies into oncology practice
  • Relevant molecular mechanisms and biology behind integrative approaches
  • Impact of timing of chemotherapy administration on toxicity, response, and outcome

This journal is a member of the Committee on Publication Ethics (COPE)

 

Integrative Cancer Therapies focuses on a new and growing movement in cancer treatment. The journal emphasizes scientific understanding of alternative medicine and traditional medicine therapies, and their responsible integration with conventional health care. Integrative care includes therapeutic interventions in diet, lifestyle, exercise, stress care, and nutritional supplements, as well as experimental vaccines, chrono-chemotherapy, and other advanced treatments. The journal presents scientifically rigorous original research, case studies, current literature reviews, educational roundtables, and commentary on key topics such as: treatment strategies, evaluations of current therapies, models for integrating complementary and conventional treatment in clinical practice, interventions from alternative and traditional medicine, implementing quality-of-life assessment and counseling in the clinical setting, cancer rehabilitation during and following cancer treatments, potential interactions of cancer chemotherapy drugs with frequently used dietary supplements, implementing integrative cancer care strategies into oncology practice, relevant molecular mechanisms and biology behind integrative approaches, impact of timing of chemotherapy administration on toxicity, response, and outcome by leading oncologists, researchers, and health-care professionals. Three unique features of this publication are: Integrative Grand Rounds - insightful case studies from all viewpoints of case management plus commentary from the editors. Point/Counterpoint -- lively discussions of controversial issues such as the interaction of antioxidants supplements and cancer chemotherapy or the effects of soy in treating breast cancer Patient's Perspective- authoritative analysis of new treatments being actively used by patients. This journal will be of particular interest to: medical, surgical, and radiation oncologists; clinical specialists frequently concerned with cancer such as urologists, gynecologists and women's health specialists; oncology and medical nurses; chiropractors; dietitians; pharmacists; and sophisticated lay people.

Associate Editor
Penny Block, PhD Block Center for Integrative Cancer Treatment
Managing Editor
Charlotte Gyllenhaal, PhD Institute for Integrative Cancer Care
International Editor
Jacob Shoham, MD, PhD Bar-Ilan University, Ramat-Gan, Israel
Assistant Editors
Advisory Board Members
James S. Gordon, MD Center for Mind-Body Medicine
William J.M. Hrushesky, MD Dorn Veterans Affairs Medical Center
Wayne Jonas, MD Uniformed Services University of the Health Sciences
John Pezzuto, PhD Purdue University, USA
Azra Raza, MD Rush Presbyterian Hospital
Julia Rowland, PhD National Cancer Institute
Leslie Sandlow, MD University of Illinois at Chicago, USA
Stephen P. Tomasovic, PhD MD Anderson Cancer Center
Debu Tripathy, MD University of Southern California, USA
Nicholas Vogelzang, MD Nevada Cancer Institute
Editorial Board
Dave Blask, PhD, MD Bassett Research Institute
Phyllis Bowen, PhD University of Illinois at Chicago, USA
D. Barry Boyd, MD Integrative Oncology
Terence Bugno, MD Northern Illinois Center for Cancer Care
Raymond Chang, MD Institute of East-West Medicine
Lorenzo Cohen, PhD M.D. Anderson Cancer Center
Geoffrey Cordell, PhD University of Illinois at Chicago, USA
Michael de la Torre, MD Block Center for Integrative Cancer Treatment
Jeremy Geffen, MD Geffen Visions International
Steven Greer, MD St. Raphael's Hospice
Michael J. Hawkins, MD Washington Cancer Institute
Arika Hirsch, MD Associated Radiologists, Ltd
Judith Jacobson, MD Columbia University College of Physicians and Surgeons
John Knaus, DO St. Francis Hospital
Lawrence Kushi, ScD Columbia University Teachers College
Brian Lawenda 21st Century Oncology
Robert A. Nagourney, MD Rational Therapeutics Inc
Alfred I. Neugut, MD, PhD Columbia University Presbyterian Hospital
Mark Renneker, MD University of California, San Francisco, USA
Stephen M. Sagar, MD Hamilton Regional Cancer Centre
Carole M. Schneider, PhD University of Northern Colorado
Victor S. Sierpina University of Texas
Lydia Temoshok, PhD Maryland Biotechnology Center
Jeanne Wallace Nutritional Solutions
Editorial Consultants
Mark Blumenthal Executive Director, American Botanical Council
Michael Broffman, LAc Pine Street Clinic
Gar Hildenbrand Gerson Research Organization
Mark Myers, RD Institute for Integrative Cancer Care
Donald R. Yance Jr., CN, MH, AHG Centre for Natural Healing
  • AgBiotech News and Information
  • AgBiotechNet
  • CAB Abstracts (Index Veterinarius, Veterinary Bulletin)
  • CAB Health
  • CABI: Abstracts on Hygiene and Communicable Diseases
  • CABI: CAB Abstracts
  • CABI: Forest Products Abstracts
  • CABI: Forestry Abstracts
  • CABI: Global Health
  • CABI: Nutrition Abstracts and Reviews Series A
  • CABI: Review of Aromatic and Medicinal Plants
  • CABI: Tropical Diseases Bulletin
  • CINAHL
  • Chemical Abstracts Service (CAS)
  • EMBASE
  • Elsevier BIOBASE/Current Awareness in Biological Sciences
  • Horticultural Science Abstracts
  • Index Medicus
  • InfoTrac (full text)
  • MEDLINE
  • Postharvest News and Information
  • ProQuest: International Pharmaceutical Abstracts
  • Rural Development Abstracts
  • Science Citation Index Expanded (Web of Science)
  • Scopus
  • Soybean Abstracts
  • This Journal is a member of the Committee on Publication Ethics

    This Journal recommends that authors follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals formulated by the International Committee of Medical Journal Editors (ICMJE)

    Please read the guidelines below then visit the Journal’s submission site https://mc.manuscriptcentral.com/ict to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.

    Only manuscripts of sufficient quality that meet the aims and scope of Integrative Cancer Therapies will be reviewed.

    As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.

    1) Open Access

    2) Article Processing Charge (APC)

    3) Article types

    4) Editorial policies

    4.1) Peer Review Policy

    4.2) Authorship

    4.3) Acknowledgments

    4.4) Funding

    4.5) Declaration of conflicting interests

    4.6) Research ethics and patient consent

    4.7) Clinical Trials

    4.8) Reporting guidelines

    4.9) Data

    5) Publishing policies

    5.1) Publication ethics

    5.2) Contributor’s publishing agreement

    5.3) Permissions

    6) Preparing your manuscript

    6.1) Word processing formats

    6.2) Artwork, figures and other graphics

    6.3) Supplementary material

    6.4) Journal layout

    6.5) Reference style

    6.6) English language editing services

    7) Submitting your manuscript

    7.1) How to submit your manuscript

    7.2) Title, keywords and abstracts

    7.3) Corresponding author contact details

    8) On acceptance and publication

    8.1) SAGE Production

    8.2) Continuous publication

    9) Further information

    1. Open Access

    In 2016, Integrative Cancer Therapies will become an open access, peer-reviewed journal. Each article accepted by peer review will be made freely available online immediately upon publication, published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of Article Processing Charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.

    For general information on open access at SAGE please visit the Open Access page or view our Open Access FAQs.

    [Return to top]

    2. Article Processing Charge (APC)

    Note: Accepted manuscripts submitted before Nov. 1, 2015 will not be assessed an APC.

    For manuscripts submitted after Nov. 1, 2015:
    If, after peer review, your manuscript is accepted for publication, a one-time Article Processing Charge (APC) is payable. This APC covers the cost of publication and ensures that your article will be freely available online in perpetuity under a Creative Commons license.

    An introductory Article Processing Charge (APC) of $900 discounted from the full rate of $1800 is available for a limited time.

    [Return to top]

    3. Article types

    Types of manuscripts accepted

    1. Research articles should contain the following sections: Introduction (with brief literature review), Methods, Results, Discussion, and Conclusions, and may be up to 35 double-spaced manuscript pages in length. Studies submitted should conscientiously adhere to ethical principles and practices, including informed consent in experiments involving human subjects, and humane practices in experiments on laboratory animals, and must mention obtaining ethical approval from the appropriate institutional board. Brief reports on preliminary research projects, of up to 10 manuscript pages, are also welcomed.

    2. Review papers should include scholarly considerations and clinical implications, and may be up to 65 double-spaced manuscript pages in length.

    3. Case reports should explain the significance of the case, including relevant patient information, results of diagnostic tests, description of treatment and outcome, and may be up to 10 double-spaced manuscript pages in length.

    4. Educational articles provide shorter summaries of the state of research or practice in a facet of integrative cancer treatment. They may be up to 45 double-spaced manuscript pages in length, should include a reference list, and should chiefly address the interests of practitioners.

    5. Letters to the Editor of up to 1000 words in length will be considered. Those wishing to submit an Integrative Tumor Board or Point-Counterpoint should contact the editors.

    6. Commentaries. These brief articles can be up to 10 manuscript pages in length.

    [Return to top]

    4. Editorial policies

    4.1 Peer review policy

    Following a preliminary triage to eliminate submissions unsuitable for Integrative Cancer Therapies all papers are sent out for review. The cover letter is important. To help the Editor in his preliminary evaluation, please indicate why you think the paper suitable for publication. The journal’s policy is to have manuscripts reviewed by two expert reviewers. Integrative Cancer Therapies utilizes a single-blind peer review process in which the reviewer’s name and information is withheld from the author. Reviewers may at their own discretion opt to reveal their names to the author in their review but our standard policy practice is for their identities to remain concealed. All manuscripts are reviewed as rapidly as possible, while maintaining rigor. Reviewers make comments to the author and recommendations to the Editor-in-Chief who then makes the final decision.

    FOR JOURNALS USING RECOMMENDED/OPPOSED REVIEWERS

    As part of the submission process you will be asked to provide the names of up to three peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:

    • The reviewer should have no prior knowledge of your submission

    • The reviewer should not have recently collaborated with any of the authors

    • Reviewer nominees from the same institution as any of the authors are not permitted

    Please note that the Editors are not obliged to invite any recommended/opposed reviewers to assess your manuscript.

    [Return to top]

    4.2 Authorship

    Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.

    The list of authors should include all those who can legitimately claim authorship. This is all those who:

    (i) Made a substantial contribution to the concept and design, acquisition of data or analysis and interpretation of data,

    (ii) Drafted the article or revised it critically for important intellectual content,

    (iii) Approved the version to be published.

    Authors should meet the conditions of all of the points above. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
    When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.

    Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.

    [Return to top]

    4.3 Acknowledgements

    All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

    Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.

    4.3.1 Writing assistance

    Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance”).

    It is not necessary to disclose use of language polishing services.

    [Return to top]

    4.4 Funding

    To comply with the guidance for Research Funders, Authors and Publishers issued by the Research Information Network (RIN), ICT additionally requires all Authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

    [Return to top]

    4.5 Declaration of conflicting interests

    It is the policy of Integrative Cancer Therapies to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.

    Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.

    For guidance on conflict of interest statements, please see the ICMJE recommendations.

    [Return to top]

    4.6 Research ethics and patient consent

    Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.

    Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

    For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

    Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.

    Please also refer to the ICMJE Recommendations for the Protection of Research Participants

    All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors.

    [Return to top]

    4.7 Clinical trials

    Integrative Cancer Therapies endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The trial registry name and URL, and registration number must be included at the end of the abstract.

    [Return to top]

    4.8 Reporting guidelines

    The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart as a cited figure, and a completed CONSORT checklist as a supplementary file.

    Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives

    [Return to top]

    4.9 Data

    SAGE acknowledges the importance of research data availability as an integral part of the research and verification process for academic journal articles.

    Integrative Cancer Therapies requests all authors submitting any primary data used in their research articles if the articles are accepted to be published in the online version of the journal, or provide detailed information in their articles on how the data can be obtained. This information should include links to third-party data repositories or detailed contact information for third-party data sources. Data available only on an author-maintained website will need to be loaded onto either the journal’s platform or a third-party platform to ensure continuing accessibility. Examples of data types include but are not limited to statistical data files, replication code, text files, audio files, images, videos, appendices, and additional charts and graphs necessary to understand the original research. The editor(s) may consider limited embargoes on proprietary data. The editor(s) can also grant exceptions for data that cannot legally or ethically be released. All data submitted should comply with Institutional or Ethical Review Board requirements and applicable government regulations. For further information, please contact the editorial office at cgyllenhaal@blockmedical.com.

    [Return to top]

    5. Publishing policies

    5.1 Publication ethics

    SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.

    5.1.1 Plagiarism

    Integrative Cancer Therapies and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of articles published in the journal. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked using duplication-checking software. Where an article is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article (removing it from the journal); taking up the matter with the head of department or dean of the author’s institution and/or relevant academic bodies or societies; banning the author from publication in the journal or all SAGE journals, or appropriate legal action.

    [Return to top]

    5.2 Contributor’s publishing agreement

    Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Integrative Cancer Therapies publishes manuscripts under Creative Commons licenses. The standard Integrative Cancer Therapies license is Creative Commons by Attribution Non-Commercial (CC BY-NC 3.0), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page

    Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request.

    [Return to top]

    5.3 Permissions

    Authors are responsible for obtaining permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.

    [Return to top]

    6. Preparing your manuscript

    6.1 Word processing formats

    Preferred formats for the text and tables of your manuscript are Word DOC, RTF, XLS. LaTeX files are also accepted. The text should be double-spaced throughout and with a minimum of 3cm for left and right hand margins and 5cm at head and foot. Text should be standard 10 or 12 point. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.

    [Return to top]

    6.2 Artwork, figures and other graphics

    For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines

    Figures supplied in color will appear in color online.

    [Return to top]

    6.3 Supplementary material

    This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. These will be subjected to peer-review alongside the article. For more information please refer to our guidelines on submitting supplementary files, which can be found within our Manuscript Submission Guidelines page.

    [Return to top]

    6.4 Journal layout

    Integrative Cancer Therapies conforms to the SAGE house style. Click here to review guidelines on SAGE House Style.

    [Return to top]

    6.5 Reference style

    Integrative Cancer Therapies adheres to the AMA reference style. Please review the guidelines on AMA to ensure your manuscript conforms to this reference style.

    [Return to top]

    6.6 English language editing services

    Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.

    [Return to top]

    7. Submitting your manuscript

    7.1 How to submit your manuscript

    Integrative Cancer Therapies is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit https://mc.manuscriptcentral.com/ict to login and submit your article online.

    IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.

    [Return to top]

    7.2 Title, keywords and abstracts

    Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting the SAGE Journal Author Gateway for guidelines on How to Help Readers Find Your Article Online.

    [Return to top]

    7.3 Corresponding author contact details

    Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article.

    [Return to top]

    8. On acceptance and publication

    If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been check for SAGE Production, the corresponding author will be asked to pay the Article Processing Charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 24 working days. Please note that no production work will occur on your paper until the APC has been received.

    [Return to top]

    8.1 SAGE Production

    Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly.

    [Return to top]


    8.2 Continuous publication

    One of the many benefits of publishing your research in an open access journal is the speed to publication. With no issues to fill and no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download. Check the ‘Latest Articles’ tab on the journal website for the latest published content. Articles are batched every quarter, and are then available in the Archive.

    [Return to top]

    9. Further Information

    Any correspondence, queries or additional requests for information on the Manuscript Submission process should be sent to the Editorial Office as follows:

    Keith I. Block, M.D.,
    Editor-in-Chief, Integrative Cancer Therapies
    Block Center for Integrative Cancer Treatment
    5230 Old Orchard Road
    Skokie IL 60077
    Telephone: 847-492-3040

    For inquiries about the status of manuscripts after submission, please contact:

    Charlotte Gyllenhaal, Ph.D.,
    Managing Editor, Integrative Cancer Therapies
    Block Center for Integrative Cancer Treatment
    5230 Old Orchard Road
    Skokie IL 60077
    Telephone: 847-492-3040
    E-mail:
    cgyllenhaal@blockmedical.com

    To subscribe to Integrative Cancer Therapies, please visit http://ict.sagepub.com.

    [Return to top]

    Please select a format:

    Individual Subscription, Print Only


    Institutional Subscription, Print Only


    Individual, Single Print Issue


    Institutional, Single Print Issue